Rocket Pharmaceuticals Files 8-K

TL;DR

Rocket Pharma filed a standard 8-K, no major news.

AI Summary

Rocket Pharmaceuticals, Inc. filed an 8-K on June 28, 2024, reporting other events and financial statements. The company, formerly known as Inotek Pharmaceuticals Corp, is incorporated in Delaware and headquartered in New York, NY. This filing does not appear to contain specific financial transaction details or significant operational updates beyond the standard reporting requirements.

Why It Matters

This filing indicates Rocket Pharmaceuticals is meeting its regulatory reporting obligations. Investors should review the full document for any specific disclosures that may impact the company's valuation or operations.

Risk Assessment

Risk Level: low — The filing is a routine 8-K report and does not disclose any new material events, risks, or significant financial changes.

Key Players & Entities

• Rocket Pharmaceuticals, Inc. (company) — Registrant
• Inotek Pharmaceuticals Corp (company) — Former company name
• June 28, 2024 (date) — Date of report
• Delaware (jurisdiction) — State of incorporation
• New York, NY (location) — Principal executive offices location

FAQ

Key Financial Figures

• $0.01 — nge on which registered Common stock, $0.01 par value RCKT The Nasdaq Global Ma

Filing Documents

• ef20031912_8k.htm (8-K) — 30KB
• ef20031912_ex99-1.htm (EX-99.1) — 18KB
• image00001.jpg (GRAPHIC) — 4KB
• 0001140361-24-031749.txt ( ) — 193KB
• rckt-20240628.xsd (EX-101.SCH) — 4KB
• rckt-20240628_lab.xml (EX-101.LAB) — 21KB
• rckt-20240628_pre.xml (EX-101.PRE) — 16KB
• ef20031912_8k_htm.xml (XML) — 4KB

01

Item 8.01. Other Events. On June 28, 2024, Rocket Pharmaceuticals, Inc. (the "Company") announced a regulatory update for KRESLADI (marnetegragene autotemcel; marne-cel), a lentiviral ("LV") vector-based gene therapy to treat severe leukocyte adhesion deficiency-I ("LAD-I"). The U.S. Food and Drug Administration ("FDA") has issued a Complete Response Letter ("CRL") in response to the Company's Biologics License Application ("BLA") for KRESLADI wherein the FDA requested limited additional Chemistry Manufacturing and Controls ("CMC") information to complete its review. The Company met with FDA senior leaders from the Center for Biologics Evaluation and Research to align on the limited scope of additional CMC information needed to support approval of KRESLADI TM as quickly as possible. A copy of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated into this report by reference.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release of Rocket Pharmaceuticals, Inc. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Rocket Pharmaceuticals, Inc. Date: June 28, 2024 By: /s/ Aaron Ondrey Aaron Ondrey Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR